Antitumor cell-complex vaccines employing genetically modified tumor cells and fibroblasts

Toxins

Volumn 6, Issue 2, 2014, Pages 636-649

  Miguel, Antonio ^a   Herrero, María José ^a,b   Sendra, Luis ^a   Botella, Rafael ^c   Diaz, Ana ^a   Algás, Rosa ^d   Aliño, Salvador F ^a,c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b INSTITUTO DE INVESTIGACIÓN SANITARIA DEL HOSPITAL CLÍNICO SAN CARLOS IDISSC   (Spain)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Bystander cells; Cancer vaccines; Cell complexes; Gene therapy; Non viral

Indexed keywords

CELL COMPLEX VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMMUNOGLOBULIN G; MEMBRANE PROTEIN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENETIC TRANSFECTION; GENETICALLY MODIFIED FIBROBLAST; IMMUNE RESPONSE; MOUSE; NEOPLASM; NONHUMAN; PLASMID; SURVIVAL TIME; TUMOR CELL; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CELLS, CULTURED; FIBROBLASTS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOGLOBULIN G; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; TUMOR BURDEN;

EID: 84894038444     PISSN: 20726651     EISSN: None     Source Type: Journal    
DOI: 10.3390/toxins6020636     Document Type: Article

References (32)

1. Dunussi-Joannopoulos, K.; Dranoff, G.; Weinstein, H.J.; Ferrara, J.L.; Bierer, B.E.; Croop, J.M. Gene immunotherapy in murine acute myeloid leukemia: Granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood 1998, 91, 222-230.
2. Small, E.J.; Sacks, N.; Nemunaitis, J.; Urba, W.J.; Dula, E.; Centeno, A.S.; Nelson, W.G.; Ando, D.; Howard, C.; Borellini, F. et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin. Cancer Res. 2007, 13, 3883-3891.
3. Maio, M.; Fonsatti, E.; Lamaj, E.; Altomonte, M.; Cattarossi, I.; Santantonio, C.; Melani, C.; Belli, F.; Arienti, F.; Colombo, M.P. et al. Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol. Immunother. 2002, 51, 9-14.
4. Salgia, R.; Lynch, T.; Skarin, A.; Lucca, J.; Lynch, C.; Jung, K.; Hodi, F.S.; Jaklitsch, M.; Mentzer, S.; Swanson, S. et al. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 2003, 21, 624-630.
5. Soiffer, R.; Hodi, F.S.; Haluska, F.; Jung, K.; Gillessen, S.; Singer, S.; Tanabe, K.; Duda, R.; Mentzer, S.; Jaklitsch, M. et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol. 2003, 21, 3343-3350.
6. Moret-Tatay, I.; Diaz, J.; Marco, F.M.; Crespo, A.; Aliño, S.F. Complete tumor prevention by engineered tumor cell vaccines employing nonviral vectors. Cancer Gene Ther. 2003, 10, 887-897.
7. Nemunaitis, J.; Sterman, D.; Jablons, D.; Smith, J.W., II; Fox, B.; Maples, P.; Hamilton, S.; Borellini, F.; Lin, A.; Morali, S. et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J. Natl. Cancer Inst. 2004, 96, 326-331.
8. Herrero, M.J.; Botella, R.; Dasí, F.; Agás, R.; Sánchez, M.; Aliño, S.F. Antigens and cytokine genes in antitumor vaccines: The importance of the temporal delivery sequence in antitumor signals. Ann. N.Y. Acad. Sci. 2006, 1091, 412-424.
9. Olivares, J.; Kumar, P.; Yu, Y.; Maples, P.B.; Senzer, N.; Bedell, C.; Barve, M.; Tong, A.; Pappen, B.O.; Kuhn, J. et al. Phase I trial of TGF-{beta}2 antisense GM-CSF gene-modified autologous tumor cell (TAG) vaccine. Clin. Cancer Res. 2011, 17, 183-192.
10. Agarwalla, P.; Barnard, Z.; Fecci, P.; Dranoff, G.; Curry, W.T., Jr. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J. Immunother. 2012, 35, 385-389.
11. Zhang, X.; Shi, X.; Li, J.; Hu, Z.; Zhou, D.; Gao, J.; Tan, W. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer. J. Urol. 2012, 187, 1071-1079.
12. Dessureault, S.; Noyes, D.; Lee, D.; Dunn, M.; Janssen, W.; Cantor, A.; Sotomayor, E.; Messina, J.; Antonia, S.J. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann. Surg. Oncol. 2007, 14, 869-884.
13. Brusic, A.; Hainz, U.; Wadleigh, M.; Neuberg, D.; Su, M.; Canning, C.M.; Deangelo, D.J.; Stone, R.M.; Lee, J.S.; Mulligan, R.C. et al. Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients. Oncoimmunology 2012, 1, 1095-1103.
14. Creelan, B.C.; Antonia, S.; Noyes, D.; Hunter, T.B.; Simon, G.R.; Bepler, G.; Williams, C.C.; Tanvetyanon, T.; Haura, E.B.; Schell, M.J. et al. Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J. Immunother. 2013, 36, 442-450.
15. Veelken, H.; Mackensen, A.; Lahn, M.; Kohler, G.; Becker, D.; Franke, B.; Brennscheidt, U.; Kulmburg, P.; Rosenthal, F.M.; Keller, H. et al. A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer. Int. J. Cancer 1997, 70, 269-277.
16. Sobol, R.E.; Shawler, D.L.; Carson, C.; Van Beveren, C.; Mercola, D.; Fakhrai, H.; Garrett, M.A.; Barone, R.; Goldfarb, P.; Bartholomew, R.M. et al. Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: A Phase I study. Clin. Cancer Res. 1999, 5, 2359-2365.
17. Kang, W.K.; Park, C.; Yoon, H.L.; Kim, W.S.; Yoon, S.S.; Lee, M.H.; Park, K.; Kim, K.; Jeong, H.S.; Kim, J.A. et al. Interleukin 12 gene therapy of cancer by peritumoral injection of transduced autologous fibroblasts: Outcome of a phase I study. Hum. Gene Ther. 2001, 12, 671-684.
18. Okada, H.; Lieberman, F.S.; Edington, H.D.; Witham, T.F.; Wargo, M.J.; Cai, Q.; Elder, E.H.; Whiteside, T.L.; Schold, S.C., Jr.; Pollack, I.F. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy. J. Neurooncol. 2003, 64, 13-20.
19. Barker, S.E.; Grosse, S.M.; Siapati, E.K.; Kritz, A.; Kinnon, C.; Thrasher, A.J.; Hart, S.L. Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12. Br. J. Cancer 2007, 97, 210-217.
20. Okada, H.; Lieberman, F.S.; Walter, K.A.; Lunsford, L.D.; Kondziolka, D.S.; Bejjani, G.K.; Hamilton, R.L.; Torres-Trejo, A.; Kalinski, P.; Cai, Q. et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J. Transl. Med. 2007, 5, 67.
21. Palumbo, R.N; Zhing, X.; Wang, C. Polymer-mediated DNA vaccine delivery via bystander cells requires a proper balance between transfection efficiency and cytoxity. J. Control. Release 2012, 157, 86-93.
22. Godbey, W.T.; Wu, K.K.; Mikos, A.G. Poly(ethylenimine) and its role in gene delivery. J. Control. Release 1999, 60, 149-160.
23. Godbey, W.T.; Barry, M.A.; Saggau, P.; Wu, K.K.; Mikos, A.G. Poly(ethylenimine)-mediated transfection: A new paradigm for gene delivery. J. Biome Mater. Res. 2000, 51, 321-328.
24. Godbey, W.T.; Mikos, A.G. Recent progress in gene delivery using non-viral transfer complexes. J. Control. Release 2001, 72, 115-125.
25. Guillem, V.M.; Tormo, M.; Revert, F.; Benet, I.; García-Conde, J.; Crespo, A.; Aliño, S.F. Polyethyleneimine-based immunopolyplex for targeted gene transfer in human lymphoma cell lines. J. Gene Med. 2002, 4, 170-182.
26. Guillem, V.M.; Tormo, M.; Moret, I.; Benet, I.; García-Conde, J.; Crespo, A.; Aliño, S.F. Targeted oligonucleotide delivery in human lymphoma cell lines using a polyethyleneimine based immunopolyplex. J. Control. Release 2002, 83, 133-146.
27. Nagai, H.; Oniki, S.; Fujiwara, S.; Yoshimoto, T.; Nishigori, C. Antimelanoma immunotherapy: Clinical and preclinical applications of IL-12 family members. Immunotherapy 2010, 2, 697-709.
28. Borrello, I.; Pardoll, D. GM-CSF-based cellular vaccines: A review of the clinical experience. Cytokine Growth Factor Rev. 2002, 13, 185-193.
29. Miguel, A.; Herrero, M.J.; Sendra, L.; Botella, R.; Algás, R.; Sánchez, M.; Aliño, S.F. Comparative antitumor effect of preventive versus therapeutic vaccines employing B16 melanoma cells genetically modified to express GM-CSF and B7.2 in a murine model. Toxins 2012, 4, 1058-1081.
30. Miguel, A.; Herrero, M.J.; Sendra, L.; Botella, R.; Algás, R.; Sánchez, M.; Aliño, S.F. Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines. Cancer Gene Ther. 2013, 20, 576-581.
31. Serafini, P.; Carbley, R.; Noonan, K.A.; Tan, G.; Bronte, V.; Borrello, I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004, 64, 6337-6343.
32. Guillem, V.M.; Aliño, S.F. Transfection pathways of nonspecific and targeted PEI-polyplexes. Gene Ther. Mol. Biol. 2004, 8, 369-384.